CGTX
HEALTHCARECognition Therapeutics Inc
$1.23-0.01 (-0.81%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CGTX Today?
No stock-specific AI insight has been generated for CGTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.22$3.83
$1.23
Fundamentals
Market Cap$110M
P/E Ratio—
EPS$-0.32
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume864K
Avg Volume (10D)—
Shares Outstanding89.4M
CGTX News
20 articles- Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business UpdateYahoo Finance·May 7, 2026
- NanoViricides to Participate at D. Boral Capital Global Conference in NYCYahoo Finance·May 7, 2026
- NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDAYahoo Finance·May 6, 2026
- Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage PlansMarketbeat·Apr 13, 2026
- Cognition Therapeutics to Present at Needham Virtual Healthcare ConferenceYahoo Finance·Apr 7, 2026
- Cognition Therapeutics CEO Issues Letter to ShareholdersYahoo Finance·Mar 31, 2026
- Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ...Yahoo Finance·Mar 26, 2026
- Cognition Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 26, 2026
- Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development UpdateYahoo Finance·Mar 26, 2026
- Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial ResultsYahoo Finance·Mar 23, 2026
- Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026Yahoo Finance·Mar 17, 2026
- Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) PsychosisYahoo Finance·Mar 2, 2026
- Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy BodiesYahoo Finance·Feb 5, 2026
- Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy BodiesYahoo Finance·Jan 27, 2026
- Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy BodiesYahoo Finance·Jan 6, 2026
- Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely?Yahoo Finance·Dec 5, 2025
- Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy BodiesYahoo Finance·Dec 3, 2025
- Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceYahoo Finance·Dec 1, 2025
- Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare ConferenceYahoo Finance·Nov 20, 2025
- Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s DiseaseYahoo Finance·Nov 13, 2025
All 20 articles loaded
Price Data
Open$1.26
Previous Close$1.24
Day High$1.27
Day Low$1.17
52 Week High$3.83
52 Week Low$0.22
52-Week Range
$0.22$3.83
$1.23
Fundamentals
Market Cap$110M
P/E Ratio—
EPS$-0.32
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume864K
Avg Volume (10D)—
Shares Outstanding89.4M
About Cognition Therapeutics Inc
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of small molecule therapies targeting age-related degenerative diseases and disorders of the central nervous system and retina. The company is headquartered in Purchase, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—